📰 Altavant Sciences News
Page 3 - Altavant Sciences News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Altavant Sciences. Real-time updates on events, politics, business and more.
February 24, 2022
Currently, major driving factors for Bronchiolitis Obliterans Syndrome market include development of potential therapies such as Zambons Phase III asset,...
February 24, 2022
Currently, major driving factors for Bronchiolitis Obliterans Syndrome market include development of potential therapies such as Zambons Phase III asset,...
January 10, 2022
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
December 23, 2021
/PRNewswire/ -- The "Global Gynecology Partnering 2010-2021: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.coms offering....
December 23, 2021
/PRNewswire/ -- The "Global Gynecology Partnering 2010-2021: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.coms offering....
December 10, 2021
/PRNewswire/ -- Sumitovant Biopharma, Inc. today announced that its portfolio of four wholly-owned subsidiary companies (Urovant, Enzyvant, Altavant and...
December 10, 2021
/PRNewswire/ -- Sumitovant Biopharma, Inc. today announced that its portfolio of four wholly-owned subsidiary companies (Urovant, Enzyvant, Altavant and...
August 18, 2021
Data from the dedicated, stand-alone, ambulatory blood pressure trial will be the focus of a podium presentation Efficacy in patients with 'dry' overactive bladder, based on a post-hoc analysis
August 12, 2021
Urovant Sciences, Inc., a wholly-owned subsidiary of Sumitovant Biopharma Ltd., today announced the appointment of Betzy Estrada as executive vice president and chief human resources officer. In her
May 26, 2021
/PRNewswire/ -- Sumitovant Biopharma, Inc. today announced that its portfolio of four wholly owned subsidiary companies (Urovant, Enzyvant, Altavant and...